Question Bank › Recently unlocked door

Recently unlocked door

Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business

Calls Tested
499
Answered YES
24
Hit Rate
4.8%
rare by design

ANI Pharmaceuticals, Inc. (ANIP) — this company's answers

NO on the Q4 2016 call 2017-03-02 B+
The model's full reasoning — Q4 2016 call → NO我们只需要根据提供的文字记录回答是或否。问题是：管理层是否描述公司最近获得了一项其先前未持有的许可、批准、资格、认证、上市或访问权——由外部机构、客户、合作伙伴或机构授予，新允许公司在其先前无法销售、服务或运营的领域开展业务——并且通过该新开放门户的实际首批业务已经开始，且该访问权限所允许的大部分业务仍在后面？ 查看记录：管理层讨论终止了HPC分销协议，并收到了现金和一个未披露的NDA（新药申请）。他们希望“在不久的将来将其作为授权仿制药推出”。这听起来像是他们获得了NDA，但尚未推出产品。正在讨论Corticotropin（ACTH凝胶）——他们正在推进，但未提交sNDA，未与FDA会面。没有提到具体的近期授予的许可、批准、资格、认证、上市或访问权，且已有业务流入。他们提到了推出Inderal XL和InnoPran XL（收购后刚推出），但这些是产品收购，不是外部授予的访问权。没有提到监管批准或新上市。 记录中没有任何内容显示公司获得了新的许可或批准并已开始业务。他们提到“终止分销协议……收到现金和一个未披露的NDA”，但尚未推出。Corticotropin项目仍在进行中，没有批准。因此，答案应为“否”。 所以回答：NO。

← Back to the full ANIP analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something granted by an outside authority, customer, partner, or institution that newly allows the company to sell, serve, or operate where it previously could not — AND that real first business through that newly opened door has ALREADY BEGUN, with most of what the access permits still ahead? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) the access is REAL AND RECENTLY IN HAND — granted, completed, or effective within roughly the last few quarters, not pending, applied-for, or expected; the form may be a regulatory approval or clearance, a customer or platform qualification, a certification or accreditation, a license, a formulary or program listing, entry onto an approved-supplier roster, or any equivalent gate that previously excluded the company; (2) FIRST BUSINESS IS ALREADY FLOWING — actual initial orders, customers, shipments, enrollments, placements, or revenue attributable to the new access, occurring now, however small; and (3) management conveys that what the access opens is LARGE RELATIVE TO WHAT HAS FLOWED SO FAR — the population, market, or activity now reachable is mostly unserved, so the reported results reflect only the first trickle through the door. Answer NO if the access is still pending, hoped for, or contingent. NO if the gate was cleared but nothing has yet transacted through it. NO if the access is routine renewal of permissions the company has long held. NO if the business through the new access is already mature and substantially reflected in results. NO if the door and its significance appear only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
RDCM RADCOM Ltd. Q4 2023 2024-01-31 A
PFE Pfizer Inc. Q4 2023 2024-01-30 F
NVAX Novavax, Inc. Q3 2023 2023-11-09 F
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
CMLS Cumulus Media Inc. Q3 2022 2022-10-28 D
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
CDXC ChromaDex Corporation Q4 2021 2022-03-09 C+
VNDA Vanda Pharmaceuticals Inc. Q4 2021 2022-02-23 F
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
AMGN Amgen Inc. Q3 2018 2018-10-30 B+
MAS Masco Corporation Q3 2018 2018-10-30 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
BMY Bristol-Myers Squibb Company Q4 2016 2017-01-26 F
MAT Mattel, Inc. Q3 2016 2016-10-19 C

How the model reasoned

NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.

More from the question bank

Paid to expand: the company's growth spendinTwo-sided intensityNamed catch-up gapNew leadership already changing what the comThe product is disappearing into reorder rhyComing out of the tunnelAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.